Estrogen Receptor Alpha Expression in Ovarian Cancer Predicts Longer Overall Survival

[1]  U. Jeschke,et al.  Prognostic significance of estrogen receptor alpha and beta expression in human serous carcinomas of the ovary , 2010, Archives of Gynecology and Obstetrics.

[2]  S. Hankinson,et al.  Relationship between Epidemiologic Risk Factors and Hormone Receptor Expression in Ovarian Cancer: Results from the Nurses' Health Study , 2009, Cancer Epidemiology Biomarkers & Prevention.

[3]  Charles M Perou,et al.  Microarrays and Epidemiology: Ensuring the Impact and Accessibility of Research Findings , 2009, Cancer Epidemiology Biomarkers & Prevention.

[4]  P. Leung,et al.  Estrogen regulates Snail and Slug in the down-regulation of E-cadherin and induces metastatic potential of ovarian cancer cells through estrogen receptor alpha. , 2008, Molecular endocrinology.

[5]  Manfred Dietel,et al.  ABCC2 (MRP2, cMOAT) Can Be Localized in the Nuclear Membrane of Ovarian Carcinomas and Correlates with Resistance to Cisplatin and Clinical Outcome , 2006, Clinical Cancer Research.

[6]  H. Lage,et al.  RNA interference-triggered reversal of ABCC2-dependent cisplatin resistance in human cancer cells. , 2006, Biochemical and biophysical research communications.

[7]  C. Denkert,et al.  Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations , 2006, International journal of cancer.

[8]  G. Lazennec.  Estrogen receptor beta, a possible tumor suppressor involved in ovarian carcinogenesis. , 2006, Cancer letters.

[9]  M. Yen,et al.  Role of Estrogen and Progesterone in the Survival of Ovarian Tumors — A Study of the Human Ovarian Adenocarcinoma Cell Line OC‐117‐VGH , 2005, Journal of the Chinese Medical Association : JCMA.

[10]  H. Lage,et al.  Protection of platinum–DNA adduct formation and reversal of cisplatin resistance by anti‐MRP2 hammerhead ribozymes in human cancer cells , 2005, International journal of cancer.

[11]  H. Lage,et al.  Reversal of different drug-resistant phenotypes by an autocatalytic multitarget multiribozyme directed against the transcripts of the ABC transporters MDR1/P-gp, MRP2, and BCRP. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[12]  D. Rosen,et al.  Expression of progesterone receptor is a favorable prognostic marker in ovarian cancer. , 2005, Gynecologic oncology.

[13]  P. Pujol,et al.  Estrogens and epithelial ovarian cancer. , 2004, Gynecologic oncology.

[14]  J. Gustafsson,et al.  Estrogen and progesterone receptors in ovarian epithelial tumors , 2004, Molecular and Cellular Endocrinology.

[15]  V. Jordan,et al.  The biological role of estrogen receptors α and β in cancer , 2004 .

[16]  R. L. Baldwin,et al.  Estrogen and progesterone receptor subtype expression in normal and malignant ovarian epithelial cell cultures. , 2003, American journal of obstetrics and gynecology.

[17]  L. Belghiti,et al.  Prognostic factors in breast cancer , 2002 .

[18]  T. Tamaya,et al.  Expression of oestrogen receptor α and β in uterine endometrial and ovarian cancers , 2002 .

[19]  S. Kaye,et al.  Recent advances in the treatment of epithelial ovarian cancer , 2001, Expert opinion on investigational drugs.

[20]  G. Mor,et al.  Absence of Estrogen Receptor‐β Expression in Metastatic Ovarian Cancer , 2000 .

[21]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[22]  T. Maudelonde,et al.  Differential Expression of Estrogen Receptor-α and -β Messenger RNAs as a Potential Marker of Ovarian Carcinogenesis , 1998 .

[23]  R. Anderson,et al.  Expression of oestrogen receptor alpha and beta in cultured human ovarian surface epithelial cells. , 1998, Molecular human reproduction.

[24]  F. Akiyama,et al.  Toward the development of a universal grading system for ovarian epithelial carcinoma , 1998, Cancer.

[25]  A. Brandenberger,et al.  Estrogen receptor alpha (ER-α) and beta (ER-β) mRNAs in normal ovary, ovarian serous cystadenocarcinoma and ovarian cancer cell lines : Down-regulation of ER-β in neoplastic tissues , 1998 .

[26]  S. Howell,et al.  Tamoxifen delays the development of resistance to cisplatin in human melanoma and ovarian cancer cell lines. , 1994, British Journal of Cancer.

[27]  W. Remmele,et al.  [Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue]. , 1987, Der Pathologe.

[28]  Leslie H. Sobin,et al.  TNM Classification of Malignant Tumours, 7th Edition , 2009 .

[29]  S. Edge,et al.  Prognostic factors in breast cancer , 2005 .

[30]  K. Hirakawa,et al.  Immunohistochemical assessment for estrogen receptor and progesterone receptor status in breast cancer: Analysis for a cut-off point as the predictor for endocrine therapy , 2004, Breast cancer.

[31]  J. Kurebayashi,et al.  Endocrine-resistant breast cancer: Underlying mechanisms and strategies for overcoming resistance , 2003, Breast cancer.

[32]  G. Mor,et al.  Absence of estrogen receptor-beta expression in metastatic ovarian cancer. , 2000, Obstetrics and gynecology.

[33]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.

[34]  A. Brandenberger,et al.  Estrogen receptor alpha (ER-alpha) and beta (ER-beta) mRNAs in normal ovary, ovarian serous cystadenocarcinoma and ovarian cancer cell lines: down-regulation of ER-beta in neoplastic tissues. , 1998, The Journal of clinical endocrinology and metabolism.

[35]  T. Maudelonde,et al.  Differential expression of estrogen receptor-alpha and -beta messenger RNAs as a potential marker of ovarian carcinogenesis. , 1998, Cancer research.